Art's Under 5 NAZ Traders

[Art2Gecko]

DFIB - Cardiac Science Announces Preliminary First Quarter Revenue Results

/FROM PR NEWSWIRE LOS ANGELES 213-626-5500/
TO BUSINESS EDITOR:

Cardiac Science Announces Preliminary First Quarter Revenue Results

IRVINE, Calif., April 8 /PRNewswire-FirstCall/ -- Cardiac Science, Inc.
(Nasdaq: DFIB) a leading manufacturer of life-saving automated public-access
defibrillators (AEDs) and provider of comprehensive AED/CPR training services,
today announced that revenue for its first quarter ended March 31, 2004 is
expected to range between $15.6 and $15.9 million, representing growth of
11-13 percent over the comparable period last year.
Cardiac Science Chairman and CEO Raymond W. Cohen said, "The lower than
expected revenue growth was primarily due to softer demand in the municipal
segment of the domestic AED business combined with longer-than-expected
selling cycles for larger customers. The Company's overall growth prospects
are undiminished and we are very optimistic about the second quarter's revenue
growth given the number of prospects in our direct sales channel pipeline, and
based on the introduction of our two new AED products which will begin
shipping to customers this quarter. We believe that other than the municipal
sector, most segments of the AED market, including the markets we anticipate
will drive future revenue growth (i.e., the corporate and government workplace
markets), are growing at a healthy pace and we expect to return to revenue
growth similar to prior quarters. In short, we do not believe that the first
quarter's results are indicative of the Company's ability to grow revenue and
improve gross margins in future periods."
With respect to operating expenses and profitability, Cohen said,
"Although the Company intends to increase its marketing expenditures, we have
implemented certain cost reductions aimed at lowering our breakeven point. We
estimate that our EBIT breakeven level will be reduced from $20 million in
quarterly revenue to $18 million by the third quarter of 2004."
The Company will provide additional details and financial guidance on a
quarterly conference call and webcast following the report of Cardiac
Science's full first quarter 2004 results later this month.

About Cardiac Science
Cardiac Science develops, manufactures and markets Powerheart(R)-brand
public-access defibrillators (AEDs) and offers comprehensive AED/CPR training
and AED program management services that facilitate successful deployments.
The Company also makes the Powerheart(R) CRM(TM), the only FDA-cleared
therapeutic patient monitor that instantly and automatically treats
hospitalized cardiac patients who suffer life-threatening heart rhythms.
Cardiac Science also manufactures its AED products on a private label basis
for other leading medical companies. For more information, please visit
www.cardiacscience.com, email Cardiac Science at [e-mail] or
call 1 949 797 3800.

This news release contains "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. In addition, from
time to time the company, or its representatives, have made or may make
forward looking statements orally or in writing. The words "estimate",
"potential", "intended", "expect", "anticipate", "believe", and similar
expressions or words are intended to identify forward looking statements.
Such forward-looking statements include, but are not limited to the
achievement of future revenue growth and operating profitability. Cardiac
Science cautions that these statements are subject to substantial risks and
uncertainties and are qualified by important factors that could cause actual
results to differ materially from those reflected by the forward-looking
statements and should not be relied upon by investors when making an
investment decision. Information on these and other factors is detailed in the
Company's Form 10-K for the year ending December 31, 2003, subsequent
quarterly filings, and other documents filed by the Company with the
Securities and Exchange Commission.

For further information, please contact: Investors, Matt Clawson,
[e-mail], or Media, Len Hall, [e-mail], of Allen & Caron,
Inc., [phone], for Cardiac Science, Inc.; Roderick de Greef, Chief
Financial Officer of Cardiac Science, Inc., [phone].

SOURCE Cardiac Science, Inc.

/CONTACT: Investors, Matt Clawson, [e-mail], or Media, Len
Hall, [e-mail], of Allen & Caron, Inc., [phone], for
CardiacScience, Inc.; Roderick de Greef, Chief Financial Officer of Cardiac
Science,Inc., [phone]/

/Web site: http://www.cardiacscience.com /

Apr-08-2004 13:00 GMT
Symbols:
US;DFIB
Source PRN PR Newswire
Categories:
NWI/HEA NWI/MTC NWR/CA NWS/ERP MST/I/DRG MST/I/HEA MST/I/MDV MST/L/EN
MST/MST/I/DRG MST/MST/I/HEA MST/MST/L/EN MST/MST/S/ERP MST/R/US/CA MST/S/ERP
TGT/PRN